Among the most promising candidates for MASLD-related treatment are glucagon-like peptide-1 receptor agonists (GLP-1 RAs), given their proven efficacy in the management of obesity and T2DM–key pathogenic drivers of MASLD. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.